Market Analysis and Insights: Global Peptide-Drug Conjugates Market
The global Peptide-Drug Conjugates market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide-Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Peptide-Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Peptide-Drug Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Peptide-Drug Conjugates include AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides, Pepgen Corporation, Soricimed Biopharma and Theratechnologies, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Peptide-Drug Conjugates market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Peptide-Drug Conjugates, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Peptide-Drug Conjugates, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide-Drug Conjugates revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Peptide-Drug Conjugates market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Peptide-Drug Conjugates revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides, Pepgen Corporation, Soricimed Biopharma and Theratechnologies, etc.
By Company
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
Segment by Type
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Segment by Application
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Peptide-Drug Conjugates in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-Drug Conjugates companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-Drug Conjugates revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-Drug Conjugates Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Cell-penetrating Peptides (CPPs)
1.2.3 Cell-targeting Peptides (CTPs)
1.3 Market by Application
1.3.1 Global Peptide-Drug Conjugates Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Carcinoma
1.3.3 Sarcoma
1.3.4 Melanoma
1.3.5 Lymphoma
1.3.6 Leukemia
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-Drug Conjugates Market Perspective (2018-2029)
2.2 Global Peptide-Drug Conjugates Growth Trends by Region
2.2.1 Peptide-Drug Conjugates Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Peptide-Drug Conjugates Historic Market Size by Region (2018-2023)
2.2.3 Peptide-Drug Conjugates Forecasted Market Size by Region (2024-2029)
2.3 Peptide-Drug Conjugates Market Dynamics
2.3.1 Peptide-Drug Conjugates Industry Trends
2.3.2 Peptide-Drug Conjugates Market Drivers
2.3.3 Peptide-Drug Conjugates Market Challenges
2.3.4 Peptide-Drug Conjugates Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Peptide-Drug Conjugates by Players
3.1.1 Global Peptide-Drug Conjugates Revenue by Players (2018-2023)
3.1.2 Global Peptide-Drug Conjugates Revenue Market Share by Players (2018-2023)
3.2 Global Peptide-Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Peptide-Drug Conjugates, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Peptide-Drug Conjugates Market Concentration Ratio
3.4.1 Global Peptide-Drug Conjugates Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-Drug Conjugates Revenue in 2022
3.5 Global Key Players of Peptide-Drug Conjugates Head office and Area Served
3.6 Global Key Players of Peptide-Drug Conjugates, Product and Application
3.7 Global Key Players of Peptide-Drug Conjugates, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-Drug Conjugates Breakdown Data by Type
4.1 Global Peptide-Drug Conjugates Historic Market Size by Type (2018-2023)
4.2 Global Peptide-Drug Conjugates Forecasted Market Size by Type (2024-2029)
5 Peptide-Drug Conjugates Breakdown Data by Application
5.1 Global Peptide-Drug Conjugates Historic Market Size by Application (2018-2023)
5.2 Global Peptide-Drug Conjugates Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Peptide-Drug Conjugates Market Size (2018-2029)
6.2 North America Peptide-Drug Conjugates Market Size by Type
6.2.1 North America Peptide-Drug Conjugates Market Size by Type (2018-2023)
6.2.2 North America Peptide-Drug Conjugates Market Size by Type (2024-2029)
6.2.3 North America Peptide-Drug Conjugates Market Share by Type (2018-2029)
6.3 North America Peptide-Drug Conjugates Market Size by Application
6.3.1 North America Peptide-Drug Conjugates Market Size by Application (2018-2023)
6.3.2 North America Peptide-Drug Conjugates Market Size by Application (2024-2029)
6.3.3 North America Peptide-Drug Conjugates Market Share by Application (2018-2029)
6.4 North America Peptide-Drug Conjugates Market Size by Country
6.4.1 North America Peptide-Drug Conjugates Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Peptide-Drug Conjugates Market Size by Country (2018-2023)
6.4.3 North America Peptide-Drug Conjugates Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Peptide-Drug Conjugates Market Size (2018-2029)
7.2 Europe Peptide-Drug Conjugates Market Size by Type
7.2.1 Europe Peptide-Drug Conjugates Market Size by Type (2018-2023)
7.2.2 Europe Peptide-Drug Conjugates Market Size by Type (2024-2029)
7.2.3 Europe Peptide-Drug Conjugates Market Share by Type (2018-2029)
7.3 Europe Peptide-Drug Conjugates Market Size by Application
7.3.1 Europe Peptide-Drug Conjugates Market Size by Application (2018-2023)
7.3.2 Europe Peptide-Drug Conjugates Market Size by Application (2024-2029)
7.3.3 Europe Peptide-Drug Conjugates Market Share by Application (2018-2029)
7.4 Europe Peptide-Drug Conjugates Market Size by Country
7.4.1 Europe Peptide-Drug Conjugates Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Peptide-Drug Conjugates Market Size by Country (2018-2023)
7.4.3 Europe Peptide-Drug Conjugates Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Peptide-Drug Conjugates Market Size (2018-2029)
8.2 China Peptide-Drug Conjugates Market Size by Type
8.2.1 China Peptide-Drug Conjugates Market Size by Type (2018-2023)
8.2.2 China Peptide-Drug Conjugates Market Size by Type (2024-2029)
8.2.3 China Peptide-Drug Conjugates Market Share by Type (2018-2029)
8.3 China Peptide-Drug Conjugates Market Size by Application
8.3.1 China Peptide-Drug Conjugates Market Size by Application (2018-2023)
8.3.2 China Peptide-Drug Conjugates Market Size by Application (2024-2029)
8.3.3 China Peptide-Drug Conjugates Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Peptide-Drug Conjugates Market Size (2018-2029)
9.2 Asia Peptide-Drug Conjugates Market Size by Type
9.2.1 Asia Peptide-Drug Conjugates Market Size by Type (2018-2023)
9.2.2 Asia Peptide-Drug Conjugates Market Size by Type (2024-2029)
9.2.3 Asia Peptide-Drug Conjugates Market Share by Type (2018-2029)
9.3 Asia Peptide-Drug Conjugates Market Size by Application
9.3.1 Asia Peptide-Drug Conjugates Market Size by Application (2018-2023)
9.3.2 Asia Peptide-Drug Conjugates Market Size by Application (2024-2029)
9.3.3 Asia Peptide-Drug Conjugates Market Share by Application (2018-2029)
9.4 Asia Peptide-Drug Conjugates Market Size by Region
9.4.1 Asia Peptide-Drug Conjugates Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Peptide-Drug Conjugates Market Size by Region (2018-2023)
9.4.3 Asia Peptide-Drug Conjugates Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Type
10.2.1 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Application
10.3.1 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Country
10.4.1 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Peptide-Drug Conjugates Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Peptide-Drug Conjugates Introduction
11.1.4 AstraZeneca Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.1.5 AstraZeneca Recent Developments
11.2 Bicycle Therapeutics
11.2.1 Bicycle Therapeutics Company Details
11.2.2 Bicycle Therapeutics Business Overview
11.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Introduction
11.2.4 Bicycle Therapeutics Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.2.5 Bicycle Therapeutics Recent Developments
11.3 Cybrexa Therapeutics
11.3.1 Cybrexa Therapeutics Company Details
11.3.2 Cybrexa Therapeutics Business Overview
11.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Introduction
11.3.4 Cybrexa Therapeutics Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.3.5 Cybrexa Therapeutics Recent Developments
11.4 Esperance Pharmaceuticals
11.4.1 Esperance Pharmaceuticals Company Details
11.4.2 Esperance Pharmaceuticals Business Overview
11.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Introduction
11.4.4 Esperance Pharmaceuticals Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.4.5 Esperance Pharmaceuticals Recent Developments
11.5 Oncopeptides
11.5.1 Oncopeptides Company Details
11.5.2 Oncopeptides Business Overview
11.5.3 Oncopeptides Peptide-Drug Conjugates Introduction
11.5.4 Oncopeptides Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.5.5 Oncopeptides Recent Developments
11.6 Pepgen Corporation
11.6.1 Pepgen Corporation Company Details
11.6.2 Pepgen Corporation Business Overview
11.6.3 Pepgen Corporation Peptide-Drug Conjugates Introduction
11.6.4 Pepgen Corporation Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.6.5 Pepgen Corporation Recent Developments
11.7 Soricimed Biopharma
11.7.1 Soricimed Biopharma Company Details
11.7.2 Soricimed Biopharma Business Overview
11.7.3 Soricimed Biopharma Peptide-Drug Conjugates Introduction
11.7.4 Soricimed Biopharma Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.7.5 Soricimed Biopharma Recent Developments
11.8 Theratechnologies
11.8.1 Theratechnologies Company Details
11.8.2 Theratechnologies Business Overview
11.8.3 Theratechnologies Peptide-Drug Conjugates Introduction
11.8.4 Theratechnologies Revenue in Peptide-Drug Conjugates Business (2018-2023)
11.8.5 Theratechnologies Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
*If Applicable.